NuvOx welcomes all inquiries regarding potential opportunities for collaboration or investment. Please e-mail your inquiries to John McGonigle, Business Development Associate, at firstname.lastname@example.org
- In stroke, animal studies show that DDFPe can reduce neurological damage by 85%. A randomized, placebo controlled Phase Ib/II clinical trial is being supported by the University of Arkansas for Medical Sciences. The FDA has allowed an IND for an open-label Phase II clinical trial.
- In oncology, DDFPe is designed to reduce tumor hypoxia in order to make tumors more sensitive to radiation, chemotherapy, and/or immunotherapy. It has completed enrollment in a Phase Ib/II clinical trial in glioblastoma multiforme patients receiving radiation therapy and chemotherapy. The trial showed statistically significant evidence of tumor re-oxygenation (p=0.015) with no significant change in the oxygenation of the normally oxygenated brain tissue (p=0.65). Early results show evidence of increased overall survival. The FDA has allowed an Investigational New Drug application for a Phase II clinical trial.
- In sickle cell crisis, a pre-clinical study of acute chest syndrome in mice saw 0% survival in controls and 100% survival in treated animals. The FDA has allowed a Phase Ib clinical trial in collaboration with the University of Pittsburgh.
- In myocardial infarction, studies in mice show that DDFPe can reduce the damage to cardiac tissue from myocardial infarction by 72% when DDFPe is given after myocardial infarction is induced. NuvOx has recently received funding from the NHLBI to study the effects of DDFPe in a porcine model of myocardial infarction.
- In hemorrhagic shock, studies by the US Army showed 0% survival in controls and 100% survival in treated animals. NuvOx has partnered with Jiangsu Nhwa Pharmaceutical Co., Ltd., to develop the product in China – NuvOx retains rights in the rest of the world for treatment of hemorrhagic shock.
- In traumatic brain injury (TBI), animal studies by the US Navy showed an increase in brain tissue oxygen tension with DDFPe administration following TBI in rats.